- Home
- MLR vs NBP Comparison
MLR vs NBP Comparison
Compare MLR & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLR | NBP |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.3M | 503.8M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLR | NBP |
|---|---|---|
| Price | $40.64 | $3.75 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $55.00 | N/A |
| AVG Volume (30 Days) | 80.1K | ★ 928.2K |
| Earning Date | 03-04-2026 | 02-14-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $840,260,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.03 | N/A |
| P/E Ratio | $15.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.81 | $0.60 |
| 52 Week High | $70.06 | $6.79 |
Technical Indicators
Market Signals| Indicator | MLR | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | N/A |
| Support Level | $39.15 | N/A |
| Resistance Level | $39.97 | N/A |
| Average True Range (ATR) | 1.24 | 0.00 |
| MACD | 0.30 | 0.00 |
| Stochastic Oscillator | 100.00 | 0.00 |
Price Performance
Historical ComparisonAbout MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.